Alvotech (ICE:ALVO)
1,090.00
-15.00 (-1.36%)
At close: Apr 16, 2025
Alvotech Revenue
In the year 2024, Alvotech had annual revenue of $491.98M USD with 426.84% growth. Alvotech had revenue of $153.34M in the quarter ending December 31, 2024, with 177.38% growth.
Revenue
$491.98M
Revenue Growth
+426.84%
P/S Ratio
4.69
Revenue / Employee
$486.14K
Employees
1,012
Market Cap
319.15B ISK
Revenue Chart
* This company reports financials in USD.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Marel | 250.20B |
Íslandsbanki | 62.96B |
Arion banki | 61.68B |
Sildarvinnslan Hf. | 43.52B |
Brim hf. | 58.07B |
Hagar | 177.12B |
Kvika banki | 15.14B |
Festi | 147.75B |
Alvotech News
- 21 days ago - This Is a Test From GlobeNewswire - GlobeNewsWire
- 22 days ago - Alvotech (ALVO) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 23 days ago - Alvotech Appoints Dr. Balaji V. Prasad as Chief Strategy Officer - GlobeNewsWire
- 23 days ago - Alvotech Appoints Dr. Balaji V. Prasad as Chief Strategy Officer - GlobeNewsWire
- 23 days ago - Alvotech Reports Record Results for 2024 and Provides Business Update - GlobeNewsWire
- 23 days ago - Alvotech Reports Record Results for 2024 and Provides Business Update - GlobeNewsWire
- 24 days ago - UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab) - GlobeNewsWire
- 24 days ago - UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab) - GlobeNewsWire